Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo Nordisk CEO: Oral Semaglutide Launch In 2020, Novel Obesity Drugs Sought

03 May 2019

• By Sten Stovall

NovoNordisk — Novo Nordisk reported strong 1Q sales, with newly launched products Ozempic and Saxenda leading the way • Source: Shutterstock

Related Content

Novo Nordisk, Embark Seek Obesity Drugs That Boost Body's Energy Use

02 Nov 2018

Related Companies

Novo Nordisk A/S

Additional Topics

Sales & Earnings Companies Commercial Metabolic Disorders BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.